1052 / 1241
Limitations of RECIST
Not all therapies result in initial shrinkage yet are
effective e.g. anti-angiogenic therapies,
immunotherapies
Side effects of some therapies can hamper response
assessment
Not all lesions are best evaluated in portal venous
post contrast phase e.g. hepatocellular carcinoma,
renal cell carcinoma